Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-806 Pharmacokinetics and Drug-Drug Interaction Study in Healthy Participants
NCT06092931Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navepdekinra (2 cohorts), sponsored by DICE Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Time t and 1 more. Started Oct 2023; status: completed.
02
Drugs
navepdekinra
Beyond the preview
Go deeper on NCT06092931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092931.